Tag Archives: Diabetes treatment

For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …

For more than a century, insulin has been the foundation of type 1 diabetes care. However, even the best insulin pumps, continuous glucose monitors, and automated insulin delivery systems still cannot fully replace the body’s lost beta cells. That is why interest in stem cell islet transplant diabetes research continues …

For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …

For years, hospital admission often meant disconnecting patients from their personal diabetes devices. Continuous glucose monitors (CGMs) and insulin pumps were frequently removed, even when patients had used them successfully at home. However, the 2026 American Diabetes Association (ADA) Standards of Care introduce a significant shift in how hospitals approach …

Depression and diabetes management often overlap in ways that make treatment decisions more complicated. Patients with type 2 diabetes frequently experience depression, and depression can make daily self-care harder. However, some commonly prescribed antidepressants and psychotropic medications may contribute to weight gain, worsen insulin resistance, or complicate long-term metabolic control. …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

Why do some patients see impressive results with GLP-1 therapies while others barely respond? This question is becoming more relevant as clinicians encounter variability in outcomes. GLP-1 resistance is emerging as a possible explanation for suboptimal responses in certain individuals with diabetes. As a result, understanding how to identify and …

Why do some patients respond dramatically to GLP-1 therapies while others see little benefit? This question is becoming more relevant as GLP-1 receptor agonists gain widespread use in diabetes and weight management. Increasingly, clinicians are encountering cases of reduced response to GLP-1 therapies, where expected glycemic or weight outcomes fail …

The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …